Director of the Center for Obesity Research and Education at Temple University’s College of Public Health, Dr. David Sarwer, sits down with WHYY to discuss how Ozempic and GLP-1's are changing how we look at weight loss.
In a recent interview, Dr. Sarwer, Senior Assoicate Dean for Research and Strategic Partnerships, delves into the transformative impact of GLP-1 medications—such as Ozempic, Mounjaro, and Wegovy—on diabetes and obesity treatment. With one in eight Americans having tried these so-called "miracle drugs," their growing popularity is reflected in endorsements from numerous celebrities. However, the high cost and limited accessibility pose significant challenges, and the potential side effects may deter some individuals from using them.